Global Bipolar Disorder Market By Type of Bipolar Disorder( Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, Rapid Cycling Bipolar, Bipolar with Mixed Features, Bipolar with Seasonal Pattern, Unspecified Bipolar) By Treatment Type (Medications (Anti-Anxiety Medications, Antipsychotic Drugs, Antidepressants, Sleeping Pills, Mood Stabilizer) Psychotherapy (Interpersonal and Social Rhythm Therapy (IPSRT), Cognitive Behavioral Therapy (CBT), Psychoeducation, Family-focused Therapy) Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Others) By Age Group (Children and Adolescents, Adults, Geriatric) By Sales Channel (Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Therapy Centers) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Global Bipolar Disorder Market is Anticipated to Reach US$ ~7 Bn by 2031, Gaining CAGR of 3% from 2023- 2031.
Bipolar disorder, also known as manic-depressive disorder, is a mental health condition characterized by extreme mood swings that include episodes of mania (elevated mood and excessive energy) and depression. These mood swings can significantly impact a person's daily life, relationships, and overall functioning. The bipolar disorder market is driven by technological advancements in the treatments and diagnosis, a rising focus on personalized medicine, and supportive government legislation for R&D. Moreover, the increasing prevalence of bipolar disorders, and the growing emphasis on early intervention and prevention strategies in bipolar disorder is supporting the growth of the global bipolar disorder market.
There is an increasing focus on personalized medicine approaches in the treatment of bipolar disorder. This involves tailoring treatments based on an individual's unique genetic profile, biomarkers, and response to medications. Personalized medicine aims to optimize treatment outcomes and reduce side effects by selecting the most suitable medication and dosage for each patient. Personalized medicine in psychiatric disorders is still in its early stages, however promising techniques for complicated illness therapy have been created using human genome sequencing. For example, researchers have used several gene combinations to pursue precision medicine or psychiatry for bipolar illness. Thus, the ongoing clinical trials and research will upsurge the global bipolar disorder market during the forecast period.
Global Bipolar Disorder Market Revenue & Forecast, (US$ Million), 2015 – 2031
Bipolar disorder can be treated through various approaches, including medication, psychotherapy, and other interventions. Medications account for a significant share of the global bipolar disorder market.
Mood Stabilizers: Medications like lithium, valproate, and carbamazepine are commonly used to stabilize mood and prevent or reduce the frequency and intensity of manic and depressive episodes.
Antipsychotic Drugs: Atypical antipsychotic medications, such as risperidone, quetiapine, and olanzapine, may be prescribed to help manage symptoms during manic or mixed episodes. This segment accounted for more than 34.5% of the total market share under the medications category.
Antidepressants: In some cases, antidepressant medications like selective serotonin reuptake inhibitors (SSRIs) or other classes may be prescribed to address depressive symptoms. However, they are often used cautiously due to the risk of triggering manic episodes.
Anti-Anxiety Medications: Benzodiazepines or other anti-anxiety medications may be used on a short-term basis to manage severe anxiety or agitation during manic or mixed episodes.
Sleeping Pills: Sleep aids or sedative medications can be prescribed to help regulate sleep patterns, especially during episodes of insomnia or disrupted sleep.
Additionally, advances in treatment options, including medication, psychotherapy techniques, and other interventions, have enhanced the management of bipolar disorder. More targeted and personalized treatment approaches are being developed to address the unique needs and symptoms of individuals with bipolar disorder.
In the Asia-Pacific region, bipolar disorder is a significant mental health concern that affects a considerable number of individuals. Efforts to raise awareness and improve education about bipolar disorder is gaining prominence in the Asia-Pacific region. Promoting mental health literacy, reducing stigma, and providing training for healthcare professionals can contribute to early detection, appropriate treatment, and better management of bipolar disorder. Ongoing research and collaboration among healthcare professionals, researchers, and policymakers in the Asia-Pacific region are crucial for advancing understanding of bipolar disorder, developing culturally appropriate interventions, and improving mental health support systems. Thus, the Asia Pacific region is expected to witness highest CAGR over the forecast period the bipolar disorder market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global bipolar disorder market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global bipolar disorder market are
- Alembic Pharmaceuticals
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- GSK plc.
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc
- Validus Pharmaceuticals, Inc.
- Other Industry Participants
Global Bipolar Disorder Market:
By Type of Bipolar Disorder
Bipolar I Disorder
Bipolar II Disorder
Cyclothymic Disorder
Rapid cycling bipolar
Bipolar with mixed features
Bipolar with seasonal pattern
Unspecified bipolar
By Treatment Type
Medications
Anti-anxiety medications
Antipsychotic drugs
Antidepressants
Sleeping pills
Mood Stabilizer
Psychotherapy
Interpersonal and social rhythm therapy (IPSRT)
Cognitive behavioral therapy (CBT)
Psychoeducation
Family-focused therapy
Electroconvulsive therapy (ECT)
Transcranial Magnetic Stimulation (TMS)
Others
By Age Group
Children and Adolescents
Adults
Geriatric
By Sales Channel
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
Therapy Centers
By Region
North America (U.S., Canada, Mexico, Rest of North America)
Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2022
1.2.3. Forecast Years: 2023 – 2031
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market
Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Bipolar Disorder Market
6. Market Synopsis:
Bipolar Disorder Market
7. Bipolar Disorder Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Bipolar Disorder Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Bipolar Disorder Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Bipolar Disorder Market
7.7.1.1.
8. Global Bipolar Disorder Market Analysis and Forecasts, 2023 –
2031
8.1. Overview
8.1.1. Global Bipolar Disorder Market Revenue (US$ Mn)
8.2. Global
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Type of Bipolar
Disorder
8.2.1. Bipolar I Disorder
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2022
8.2.1.3. Market Forecast, 2023 - 2031
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2022
8.2.1.5.1.2. Market
Forecast, 2023 - 2031
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2022
8.2.1.5.2.2. Market
Forecast, 2023 - 2031
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2022
8.2.1.5.3.2. Market
Forecast, 2023 - 2031
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2022
8.2.1.5.4.2. Market
Forecast, 2023 - 2031
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2022
8.2.1.5.5.2. Market
Forecast, 2023 - 2031
8.2.2. Bipolar II Disorder
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2022
8.2.2.3. Market Forecast, 2023 - 2031
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2022
8.2.2.5.1.2. Market
Forecast, 2023 - 2031
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2022
8.2.2.5.2.2. Market
Forecast, 2023 - 2031
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2022
8.2.2.5.3.2. Market
Forecast, 2023 - 2031
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2022
8.2.2.5.4.2. Market
Forecast, 2023 - 2031
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2022
8.2.2.5.5.2. Market
Forecast, 2023 - 2031
8.2.3. Cyclothymic Disorder
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2022
8.2.3.3. Market Forecast, 2023 - 2031
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2022
8.2.3.5.1.2. Market
Forecast, 2023 - 2031
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2022
8.2.3.5.2.2. Market
Forecast, 2023 - 2031
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2022
8.2.3.5.3.2. Market
Forecast, 2023 - 2031
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2022
8.2.3.5.4.2. Market
Forecast, 2023 - 2031
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2022
8.2.3.5.5.2. Market
Forecast, 2023 - 2031
8.2.4. Rapid cycling bipolar
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2022
8.2.4.3. Market Forecast, 2023 - 2031
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2022
8.2.4.5.1.2. Market
Forecast, 2023 - 2031
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2022
8.2.4.5.2.2. Market
Forecast, 2023 - 2031
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2022
8.2.4.5.3.2. Market
Forecast, 2023 - 2031
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2022
8.2.4.5.4.2. Market
Forecast, 2023 - 2031
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2022
8.2.4.5.5.2. Market
Forecast, 2023 - 2031
8.2.5. Bipolar with mixed features
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2022
8.2.5.3. Market Forecast, 2023 - 2031
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2022
8.2.5.5.1.2. Market
Forecast, 2023 - 2031
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2022
8.2.5.5.2.2. Market
Forecast, 2023 - 2031
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2022
8.2.5.5.3.2. Market
Forecast, 2023 - 2031
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2022
8.2.5.5.4.2. Market
Forecast, 2023 - 2031
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2022
8.2.5.5.5.2. Market
Forecast, 2023 - 2031
8.2.6. Bipolar with seasonal pattern
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2022
8.2.6.3. Market Forecast, 2023 - 2031
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market
Estimation, 2015 - 2022
8.2.6.5.1.2. Market
Forecast, 2023 - 2031
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 - 2022
8.2.6.5.2.2. Market
Forecast, 2023 - 2031
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market
Estimation, 2015 - 2022
8.2.6.5.3.2. Market
Forecast, 2023 - 2031
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 - 2022
8.2.6.5.4.2. Market
Forecast, 2023 - 2031
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market
Estimation, 2015 - 2022
8.2.6.5.5.2. Market
Forecast, 2023 - 2031
8.2.7. Unspecified bipolar
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 - 2022
8.2.7.3. Market Forecast, 2023 - 2031
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market
Estimation, 2015 - 2022
8.2.7.5.1.2. Market
Forecast, 2023 - 2031
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 - 2022
8.2.7.5.2.2. Market
Forecast, 2023 - 2031
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market
Estimation, 2015 - 2022
8.2.7.5.3.2. Market
Forecast, 2023 - 2031
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 - 2022
8.2.7.5.4.2. Market
Forecast, 2023 - 2031
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market
Estimation, 2015 - 2022
8.2.7.5.5.2. Market
Forecast, 2023 - 2031
8.3. Key
Segment for Channeling Investments
8.3.1. By Type of Bipolar Disorder
9. Global Bipolar Disorder Market Analysis and Forecasts, 2023 –
2031
9.1. Overview
9.2. Global
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Treatment Type
9.2.1. Medications (Definition, Market Estimation and Penetration,
2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 – 2031), Compound Annual
Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific,
Middle East and Africa, Latin America) and Information on Anti-anxiety
medications, Antipsychotic drugs, Antidepressants, Sleeping pills, Mood
Stabilizer )
9.2.1.1. Anti-anxiety medications
9.2.1.2. Antipsychotic drugs
9.2.1.3. Antidepressants
9.2.1.4. Sleeping pills
9.2.1.5. Mood Stabilizer
9.2.2. Psychotherapy (Definition, Market Estimation and Penetration,
2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 – 2031),
Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America,
Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on
Interpersonal and Social Rhythm Therapy (IPSRT), Cognitive Behavioral Therapy
(CBT), Psychoeducation, Family-focused therapy)
9.2.2.1. Interpersonal and Social Rhythm Therapy (IPSRT)
9.2.2.2. Cognitive Behavioral Therapy (CBT)
9.2.2.3. Psychoeducation
9.2.2.4. Family-focused therapy
9.2.3. Electroconvulsive therapy (ECT)
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2022
9.2.3.3. Market Forecast, 2023 - 2031
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2022
9.2.3.5.1.2. Market
Forecast, 2023 - 2031
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2022
9.2.3.5.2.2. Market
Forecast, 2023 - 2031
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2022
9.2.3.5.3.2. Market
Forecast, 2023 - 2031
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2022
9.2.3.5.4.2. Market
Forecast, 2023 - 2031
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2022
9.2.3.5.5.2. Market
Forecast, 2023 - 2031
9.2.4. Transcranial Magnetic Stimulation (TMS)
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2022
9.2.4.3. Market Forecast, 2023 - 2031
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2022
9.2.4.5.1.2. Market
Forecast, 2023 - 2031
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2022
9.2.4.5.2.2. Market
Forecast, 2023 - 2031
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2022
9.2.4.5.3.2. Market
Forecast, 2023 - 2031
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2022
9.2.4.5.4.2. Market
Forecast, 2023 - 2031
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2022
9.2.4.5.5.2. Market
Forecast, 2023 - 2031
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2022
9.2.5.3. Market Forecast, 2023 - 2031
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2022
9.2.5.5.1.2. Market
Forecast, 2023 - 2031
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2022
9.2.5.5.2.2. Market
Forecast, 2023 - 2031
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2022
9.2.5.5.3.2. Market
Forecast, 2023 - 2031
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2022
9.2.5.5.4.2. Market
Forecast, 2023 - 2031
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2022
9.2.5.5.5.2. Market
Forecast, 2023 - 2031
9.3. Key
Segment for Channeling Investments
9.3.1. By Treatment Type
10. Global Bipolar Disorder Market Analysis and Forecasts, 2023 –
2031
10.1. Overview
10.2. Global
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Age Group
10.2.1. Children and Adolescents
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2022
10.2.1.3. Market Forecast, 2023 - 2031
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2022
10.2.1.5.1.2. Market
Forecast, 2023 - 2031
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2022
10.2.1.5.2.2. Market
Forecast, 2023 - 2031
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2022
10.2.1.5.3.2. Market
Forecast, 2023 - 2031
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2022
10.2.1.5.4.2. Market
Forecast, 2023 - 2031
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2022
10.2.1.5.5.2. Market
Forecast, 2023 - 2031
10.2.2. Adults
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2022
10.2.2.3. Market Forecast, 2023 - 2031
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2022
10.2.2.5.1.2. Market
Forecast, 2023 - 2031
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2022
10.2.2.5.2.2. Market
Forecast, 2023 - 2031
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2022
10.2.2.5.3.2. Market
Forecast, 2023 - 2031
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2022
10.2.2.5.4.2. Market
Forecast, 2023 - 2031
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2022
10.2.2.5.5.2. Market
Forecast, 2023 - 2031
10.2.3. Geriatric
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2022
10.2.3.3. Market Forecast, 2023 - 2031
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2022
10.2.3.5.1.2. Market
Forecast, 2023 - 2031
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2022
10.2.3.5.2.2. Market
Forecast, 2023 - 2031
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2022
10.2.3.5.3.2. Market
Forecast, 2023 - 2031
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2022
10.2.3.5.4.2. Market
Forecast, 2023 - 2031
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2022
10.2.3.5.5.2. Market
Forecast, 2023 - 2031
10.3. Key
Segment for Channeling Investments
10.3.1. By Age Group
11. Global Bipolar Disorder Market Analysis and Forecasts, 2023 –
2031
11.1. Overview
11.2. Global
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Sales Channel
11.2.1. Hospitals and Clinics
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2022
11.2.1.3. Market Forecast, 2023 - 2031
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2022
11.2.1.5.1.2. Market
Forecast, 2023 - 2031
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2022
11.2.1.5.2.2. Market
Forecast, 2023 - 2031
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2022
11.2.1.5.3.2. Market
Forecast, 2023 - 2031
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2022
11.2.1.5.4.2. Market
Forecast, 2023 - 2031
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2022
11.2.1.5.5.2. Market
Forecast, 2023 - 2031
11.2.2. Retail Pharmacies
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2022
11.2.2.3. Market Forecast, 2023 - 2031
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2022
11.2.2.5.1.2. Market
Forecast, 2023 - 2031
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2022
11.2.2.5.2.2. Market
Forecast, 2023 - 2031
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2022
11.2.2.5.3.2. Market
Forecast, 2023 - 2031
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2022
11.2.2.5.4.2. Market
Forecast, 2023 - 2031
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2022
11.2.2.5.5.2. Market
Forecast, 2023 - 2031
11.2.3. Online Pharmacies
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2022
11.2.3.3. Market Forecast, 2023 - 2031
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2022
11.2.3.5.1.2. Market
Forecast, 2023 - 2031
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2022
11.2.3.5.2.2. Market
Forecast, 2023 - 2031
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2022
11.2.3.5.3.2. Market
Forecast, 2023 - 2031
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2022
11.2.3.5.4.2. Market
Forecast, 2023 - 2031
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2022
11.2.3.5.5.2. Market
Forecast, 2023 - 2031
11.2.4. Therapy Centers
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 - 2022
11.2.4.3. Market Forecast, 2023 - 2031
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market
Estimation, 2015 - 2022
11.2.4.5.1.2. Market
Forecast, 2023 - 2031
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 - 2022
11.2.4.5.2.2. Market
Forecast, 2023 - 2031
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market
Estimation, 2015 - 2022
11.2.4.5.3.2. Market
Forecast, 2023 - 2031
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 - 2022
11.2.4.5.4.2. Market
Forecast, 2023 - 2031
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market
Estimation, 2015 - 2022
11.2.4.5.5.2. Market
Forecast, 2023 - 2031
11.3. Key
Segment for Channeling Investments
11.3.1. By Sales Channel
12. North America Bipolar Disorder Market Analysis and Forecasts,
2023 – 2031
12.1. Overview
12.1.1. North America Bipolar Disorder Market Revenue (US$ Mn)
12.2. North
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Type of
Bipolar Disorder
12.2.1. Bipolar I Disorder
12.2.2. Bipolar II Disorder
12.2.3. Cyclothymic Disorder
12.2.4. Rapid cycling bipolar
12.2.5. Bipolar with mixed features
12.2.6. Bipolar with seasonal pattern
12.2.7. Unspecified bipolar
12.3. North
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
12.3.1. Medications
12.3.1.1. Anti-anxiety medications
12.3.1.2. Antipsychotic drugs
12.3.1.3. Antidepressants
12.3.1.4. Sleeping pills
12.3.1.5. Mood Stabilizer
12.3.2. Psychotherapy
12.3.2.1. Interpersonal and Social Rhythm Therapy (IPSRT)
12.3.2.2. Cognitive Behavioral Therapy (CBT)
12.3.2.3. Psychoeducation
12.3.2.4. Family-focused therapy
12.3.3. Electroconvulsive therapy (ECT)
12.3.4. Transcranial Magnetic Stimulation (TMS)
12.3.5. Others
12.4. North
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Age Group
12.4.1. Children and Adolescents
12.4.2. Adults
12.4.3. Geriatric
12.5. North
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
12.5.1. Hospitals and Clinics
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.5.4. Therapy Centers
12.6. North
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Type of Bipolar Disorder
12.6.1.1.1. Bipolar I Disorder
12.6.1.1.2. Bipolar II Disorder
12.6.1.1.3. Cyclothymic Disorder
12.6.1.1.4. Rapid cycling bipolar
12.6.1.1.5. Bipolar with mixed features
12.6.1.1.6. Bipolar with seasonal pattern
12.6.1.1.7. Unspecified bipolar
12.6.1.2. U.S Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
12.6.1.2.1. Medications
12.6.1.2.1.1. Anti-anxiety
medications
12.6.1.2.1.2. Antipsychotic
drugs
12.6.1.2.1.3. Antidepressants
12.6.1.2.1.4. Sleeping
pills
12.6.1.2.1.5. Mood
Stabilizer
12.6.1.2.2. Psychotherapy
12.6.1.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
12.6.1.2.2.2. Cognitive
Behavioral Therapy (CBT)
12.6.1.2.2.3. Psychoeducation
12.6.1.2.2.4. Family-focused
therapy
12.6.1.2.3. Electroconvulsive therapy (ECT)
12.6.1.2.4. Transcranial Magnetic Stimulation (TMS)
12.6.1.2.5. Others
12.6.1.3. U.S Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Age Group
12.6.1.3.1. Children and Adolescents
12.6.1.3.2. Adults
12.6.1.3.3. Geriatric
12.6.1.4. U.S Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Sales Channel
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Retail Pharmacies
12.6.1.4.3. Online Pharmacies
12.6.1.4.4. Therapy Centers
12.6.2. Canada
12.6.2.1. Canada Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
12.6.2.1.1. Bipolar I Disorder
12.6.2.1.2. Bipolar II Disorder
12.6.2.1.3. Cyclothymic Disorder
12.6.2.1.4. Rapid cycling bipolar
12.6.2.1.5. Bipolar with mixed features
12.6.2.1.6. Bipolar with seasonal pattern
12.6.2.1.7. Unspecified bipolar
12.6.2.2. Canada Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
12.6.2.2.1. Medications
12.6.2.2.1.1. Anti-anxiety
medications
12.6.2.2.1.2. Antipsychotic
drugs
12.6.2.2.1.3. Antidepressants
12.6.2.2.1.4. Sleeping
pills
12.6.2.2.1.5. Mood
Stabilizer
12.6.2.2.2. Psychotherapy
12.6.2.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
12.6.2.2.2.2. Cognitive
Behavioral Therapy (CBT)
12.6.2.2.2.3. Psychoeducation
12.6.2.2.2.4. Family-focused
therapy
12.6.2.2.3. Electroconvulsive therapy (ECT)
12.6.2.2.4. Transcranial Magnetic Stimulation (TMS)
12.6.2.2.5. Others
12.6.2.3. Canada Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
12.6.2.3.1. Children and Adolescents
12.6.2.3.2. Adults
12.6.2.3.3. Geriatric
12.6.2.4. Canada Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Retail Pharmacies
12.6.2.4.3. Online Pharmacies
12.6.2.4.4. Therapy Centers
12.6.3. Mexico
12.6.3.1. Mexico Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
12.6.3.1.1. Bipolar I Disorder
12.6.3.1.2. Bipolar II Disorder
12.6.3.1.3. Cyclothymic Disorder
12.6.3.1.4. Rapid cycling bipolar
12.6.3.1.5. Bipolar with mixed features
12.6.3.1.6. Bipolar with seasonal pattern
12.6.3.1.7. Unspecified bipolar
12.6.3.2. Mexico Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
12.6.3.2.1. Medications
12.6.3.2.1.1. Anti-anxiety
medications
12.6.3.2.1.2. Antipsychotic
drugs
12.6.3.2.1.3. Antidepressants
12.6.3.2.1.4. Sleeping
pills
12.6.3.2.1.5. Mood
Stabilizer
12.6.3.2.2. Psychotherapy
12.6.3.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
12.6.3.2.2.2. Cognitive
Behavioral Therapy (CBT)
12.6.3.2.2.3. Psychoeducation
12.6.3.2.2.4. Family-focused
therapy
12.6.3.2.3. Electroconvulsive therapy (ECT)
12.6.3.2.4. Transcranial Magnetic Stimulation (TMS)
12.6.3.2.5. Others
12.6.3.3. Mexico Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
12.6.3.3.1. Children and Adolescents
12.6.3.3.2. Adults
12.6.3.3.3. Geriatric
12.6.3.4. Mexico Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Retail Pharmacies
12.6.3.4.3. Online Pharmacies
12.6.3.4.4. Therapy Centers
12.6.4. Rest of North America
12.6.4.1. Rest of North America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Type of Bipolar Disorder
12.6.4.1.1. Bipolar I Disorder
12.6.4.1.2. Bipolar II Disorder
12.6.4.1.3. Cyclothymic Disorder
12.6.4.1.4. Rapid cycling bipolar
12.6.4.1.5. Bipolar with mixed features
12.6.4.1.6. Bipolar with seasonal pattern
12.6.4.1.7. Unspecified bipolar
12.6.4.2. Rest of North America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Treatment Type
12.6.4.2.1. Medications
12.6.4.2.1.1. Anti-anxiety
medications
12.6.4.2.1.2. Antipsychotic
drugs
12.6.4.2.1.3. Antidepressants
12.6.4.2.1.4. Sleeping
pills
12.6.4.2.1.5. Mood
Stabilizer
12.6.4.2.2. Psychotherapy
12.6.4.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
12.6.4.2.2.2. Cognitive
Behavioral Therapy (CBT)
12.6.4.2.2.3. Psychoeducation
12.6.4.2.2.4. Family-focused
therapy
12.6.4.2.3. Electroconvulsive therapy (ECT)
12.6.4.2.4. Transcranial Magnetic Stimulation (TMS)
12.6.4.2.5. Others
12.6.4.3. Rest of North America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Age Group
12.6.4.3.1. Children and Adolescents
12.6.4.3.2. Adults
12.6.4.3.3. Geriatric
12.6.4.4. Rest of North America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Retail Pharmacies
12.6.4.4.3. Online Pharmacies
12.6.4.4.4. Therapy Centers
12.7. Key
Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Type of Bipolar Disorder
12.7.3. By Treatment Type
12.7.4. By Age Group
12.7.5. By Sales Channel
13. Europe Bipolar Disorder Market Analysis and Forecasts, 2023 –
2031
13.1. Overview
13.1.1. Europe Bipolar Disorder Market Revenue (US$ Mn)
13.2. Europe
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Type of Bipolar
Disorder
13.2.1. Bipolar I Disorder
13.2.2. Bipolar II Disorder
13.2.3. Cyclothymic Disorder
13.2.4. Rapid cycling bipolar
13.2.5. Bipolar with mixed features
13.2.6. Bipolar with seasonal pattern
13.2.7. Unspecified bipolar
13.3. Europe
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Treatment Type
13.3.1. Medications
13.3.1.1. Anti-anxiety medications
13.3.1.2. Antipsychotic drugs
13.3.1.3. Antidepressants
13.3.1.4. Sleeping pills
13.3.1.5. Mood Stabilizer
13.3.2. Psychotherapy
13.3.2.1. Interpersonal and Social Rhythm Therapy (IPSRT)
13.3.2.2. Cognitive Behavioral Therapy (CBT)
13.3.2.3. Psychoeducation
13.3.2.4. Family-focused therapy
13.3.3. Electroconvulsive therapy (ECT)
13.3.4. Transcranial Magnetic Stimulation (TMS)
13.3.5. Others
13.4. Europe Bipolar
Disorder Market Revenue (US$ Mn) and Forecasts, By Age Group
13.4.1. Children and Adolescents
13.4.2. Adults
13.4.3. Geriatric
13.5. Europe
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.5.1. Hospitals and Clinics
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.5.4. Therapy Centers
13.6. Europe
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
13.6.1.1.1. Bipolar I Disorder
13.6.1.1.2. Bipolar II Disorder
13.6.1.1.3. Cyclothymic Disorder
13.6.1.1.4. Rapid cycling bipolar
13.6.1.1.5. Bipolar with mixed features
13.6.1.1.6. Bipolar with seasonal pattern
13.6.1.1.7. Unspecified bipolar
13.6.1.2. France Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
13.6.1.2.1. Medications
13.6.1.2.1.1. Anti-anxiety
medications
13.6.1.2.1.2. Antipsychotic
drugs
13.6.1.2.1.3. Antidepressants
13.6.1.2.1.4. Sleeping
pills
13.6.1.2.1.5. Mood
Stabilizer
13.6.1.2.2. Psychotherapy
13.6.1.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.1.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.1.2.2.3. Psychoeducation
13.6.1.2.2.4. Family-focused
therapy
13.6.1.2.3. Electroconvulsive therapy (ECT)
13.6.1.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.1.2.5. Others
13.6.1.3. France Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
13.6.1.3.1. Children and Adolescents
13.6.1.3.2. Adults
13.6.1.3.3. Geriatric
13.6.1.4. France Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Retail Pharmacies
13.6.1.4.3. Online Pharmacies
13.6.1.4.4. Therapy Centers
13.6.2. The UK
13.6.2.1. The UK Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
13.6.2.1.1. Bipolar I Disorder
13.6.2.1.2. Bipolar II Disorder
13.6.2.1.3. Cyclothymic Disorder
13.6.2.1.4. Rapid cycling bipolar
13.6.2.1.5. Bipolar with mixed features
13.6.2.1.6. Bipolar with seasonal pattern
13.6.2.1.7. Unspecified bipolar
13.6.2.2. The UK Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
13.6.2.2.1. Medications
13.6.2.2.1.1. Anti-anxiety
medications
13.6.2.2.1.2. Antipsychotic
drugs
13.6.2.2.1.3. Antidepressants
13.6.2.2.1.4. Sleeping
pills
13.6.2.2.1.5. Mood
Stabilizer
13.6.2.2.2. Psychotherapy
13.6.2.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.2.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.2.2.2.3. Psychoeducation
13.6.2.2.2.4. Family-focused
therapy
13.6.2.2.3. Electroconvulsive therapy (ECT)
13.6.2.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.2.2.5. Others
13.6.2.3. The UK Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
13.6.2.3.1. Children and Adolescents
13.6.2.3.2. Adults
13.6.2.3.3. Geriatric
13.6.2.4. The UK Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Retail Pharmacies
13.6.2.4.3. Online Pharmacies
13.6.2.4.4. Therapy Centers
13.6.3. Spain
13.6.3.1. Spain Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
13.6.3.1.1. Bipolar I Disorder
13.6.3.1.2. Bipolar II Disorder
13.6.3.1.3. Cyclothymic Disorder
13.6.3.1.4. Rapid cycling bipolar
13.6.3.1.5. Bipolar with mixed features
13.6.3.1.6. Bipolar with seasonal pattern
13.6.3.1.7. Unspecified bipolar
13.6.3.2. Spain Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
13.6.3.2.1. Medications
13.6.3.2.1.1. Anti-anxiety
medications
13.6.3.2.1.2. Antipsychotic
drugs
13.6.3.2.1.3. Antidepressants
13.6.3.2.1.4. Sleeping
pills
13.6.3.2.1.5. Mood
Stabilizer
13.6.3.2.2. Psychotherapy
13.6.3.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.3.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.3.2.2.3. Psychoeducation
13.6.3.2.2.4. Family-focused
therapy
13.6.3.2.3. Electroconvulsive therapy (ECT)
13.6.3.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.3.2.5. Others
13.6.3.3. Spain Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
13.6.3.3.1. Children and Adolescents
13.6.3.3.2. Adults
13.6.3.3.3. Geriatric
13.6.3.4. Spain Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Retail Pharmacies
13.6.3.4.3. Online Pharmacies
13.6.3.4.4. Therapy Centers
13.6.4. Germany
13.6.4.1. Germany Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
13.6.4.1.1. Bipolar I Disorder
13.6.4.1.2. Bipolar II Disorder
13.6.4.1.3. Cyclothymic Disorder
13.6.4.1.4. Rapid cycling bipolar
13.6.4.1.5. Bipolar with mixed features
13.6.4.1.6. Bipolar with seasonal pattern
13.6.4.1.7. Unspecified bipolar
13.6.4.2. Germany Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
13.6.4.2.1. Medications
13.6.4.2.1.1. Anti-anxiety
medications
13.6.4.2.1.2. Antipsychotic
drugs
13.6.4.2.1.3. Antidepressants
13.6.4.2.1.4. Sleeping
pills
13.6.4.2.1.5. Mood
Stabilizer
13.6.4.2.2. Psychotherapy
13.6.4.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.4.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.4.2.2.3. Psychoeducation
13.6.4.2.2.4. Family-focused
therapy
13.6.4.2.3. Electroconvulsive therapy (ECT)
13.6.4.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.4.2.5. Others
13.6.4.3. Germany Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.6.4.3.1. Children and Adolescents
13.6.4.3.2. Adults
13.6.4.3.3. Geriatric
13.6.4.4. Germany Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Retail Pharmacies
13.6.4.4.3. Online Pharmacies
13.6.4.4.4. Therapy Centers
13.6.5. Italy
13.6.5.1. Italy Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
13.6.5.1.1. Bipolar I Disorder
13.6.5.1.2. Bipolar II Disorder
13.6.5.1.3. Cyclothymic Disorder
13.6.5.1.4. Rapid cycling bipolar
13.6.5.1.5. Bipolar with mixed features
13.6.5.1.6. Bipolar with seasonal pattern
13.6.5.1.7. Unspecified bipolar
13.6.5.2. Italy Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
13.6.5.2.1. Medications
13.6.5.2.1.1. Anti-anxiety
medications
13.6.5.2.1.2. Antipsychotic
drugs
13.6.5.2.1.3. Antidepressants
13.6.5.2.1.4. Sleeping
pills
13.6.5.2.1.5. Mood
Stabilizer
13.6.5.2.2. Psychotherapy
13.6.5.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.5.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.5.2.2.3. Psychoeducation
13.6.5.2.2.4. Family-focused
therapy
13.6.5.2.3. Electroconvulsive therapy (ECT)
13.6.5.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.5.2.5. Others
13.6.5.3. Italy Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
13.6.5.3.1. Children and Adolescents
13.6.5.3.2. Adults
13.6.5.3.3. Geriatric
13.6.5.4. Italy Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Retail Pharmacies
13.6.5.4.3. Online Pharmacies
13.6.5.4.4. Therapy Centers
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
13.6.6.1.1. Bipolar I Disorder
13.6.6.1.2. Bipolar II Disorder
13.6.6.1.3. Cyclothymic Disorder
13.6.6.1.4. Rapid cycling bipolar
13.6.6.1.5. Bipolar with mixed features
13.6.6.1.6. Bipolar with seasonal pattern
13.6.6.1.7. Unspecified bipolar
13.6.6.2. Nordic Countries Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
13.6.6.2.1. Medications
13.6.6.2.1.1. Anti-anxiety
medications
13.6.6.2.1.2. Antipsychotic
drugs
13.6.6.2.1.3. Antidepressants
13.6.6.2.1.4. Sleeping
pills
13.6.6.2.1.5. Mood
Stabilizer
13.6.6.2.2. Psychotherapy
13.6.6.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.6.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.6.2.2.3. Psychoeducation
13.6.6.2.2.4. Family-focused
therapy
13.6.6.2.3. Electroconvulsive therapy (ECT)
13.6.6.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.6.2.5. Others
13.6.6.3. Nordic Countries Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.6.6.3.1. Children and Adolescents
13.6.6.3.2. Adults
13.6.6.3.3. Geriatric
13.6.6.4. Nordic Countries Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Retail Pharmacies
13.6.6.4.3. Online Pharmacies
13.6.6.4.4. Therapy Centers
13.6.6.5. Nordic Countries Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
13.6.7.1.1. Bipolar I Disorder
13.6.7.1.2. Bipolar II Disorder
13.6.7.1.3. Cyclothymic Disorder
13.6.7.1.4. Rapid cycling bipolar
13.6.7.1.5. Bipolar with mixed features
13.6.7.1.6. Bipolar with seasonal pattern
13.6.7.1.7. Unspecified bipolar
13.6.7.2. Benelux Union Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
13.6.7.2.1. Medications
13.6.7.2.1.1. Anti-anxiety
medications
13.6.7.2.1.2. Antipsychotic
drugs
13.6.7.2.1.3. Antidepressants
13.6.7.2.1.4. Sleeping
pills
13.6.7.2.1.5. Mood
Stabilizer
13.6.7.2.2. Psychotherapy
13.6.7.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.7.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.7.2.2.3. Psychoeducation
13.6.7.2.2.4. Family-focused
therapy
13.6.7.2.3. Electroconvulsive therapy (ECT)
13.6.7.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.7.2.5. Others
13.6.7.3. Benelux Union Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.6.7.3.1. Children and Adolescents
13.6.7.3.2. Adults
13.6.7.3.3. Geriatric
13.6.7.4. Benelux Union Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Retail Pharmacies
13.6.7.4.3. Online Pharmacies
13.6.7.4.4. Therapy Centers
13.6.7.5. Benelux Union Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
13.6.8.1.1. Bipolar I Disorder
13.6.8.1.2. Bipolar II Disorder
13.6.8.1.3. Cyclothymic Disorder
13.6.8.1.4. Rapid cycling bipolar
13.6.8.1.5. Bipolar with mixed features
13.6.8.1.6. Bipolar with seasonal pattern
13.6.8.1.7. Unspecified bipolar
13.6.8.2. Rest of Europe Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
13.6.8.2.1. Medications
13.6.8.2.1.1. Anti-anxiety
medications
13.6.8.2.1.2. Antipsychotic
drugs
13.6.8.2.1.3. Antidepressants
13.6.8.2.1.4. Sleeping
pills
13.6.8.2.1.5. Mood
Stabilizer
13.6.8.2.2. Psychotherapy
13.6.8.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
13.6.8.2.2.2. Cognitive
Behavioral Therapy (CBT)
13.6.8.2.2.3. Psychoeducation
13.6.8.2.2.4. Family-focused
therapy
13.6.8.2.3. Electroconvulsive therapy (ECT)
13.6.8.2.4. Transcranial Magnetic Stimulation (TMS)
13.6.8.2.5. Others
13.6.8.3. Rest of Europe Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
13.6.8.3.1. Children and Adolescents
13.6.8.3.2. Adults
13.6.8.3.3. Geriatric
13.6.8.4. Rest of Europe Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Retail Pharmacies
13.6.8.4.3. Online Pharmacies
13.6.8.4.4. Therapy Centers
13.7. Key
Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Type of Bipolar Disorder
13.7.3. By Treatment Type
13.7.4. By Age Group
13.7.5. By Sales Channel
14. Asia Pacific Bipolar Disorder Market Analysis and Forecasts,
2023 – 2031
14.1. Overview
14.1.1. Asia Pacific Bipolar Disorder Market Revenue (US$ Mn)
14.2. Asia
Pacific Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Type of
Bipolar Disorder
14.2.1. Bipolar I Disorder
14.2.2. Bipolar II Disorder
14.2.3. Cyclothymic Disorder
14.2.4. Rapid cycling bipolar
14.2.5. Bipolar with mixed features
14.2.6. Bipolar with seasonal pattern
14.2.7. Unspecified bipolar
14.3. Asia
Pacific Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Treatment Type
14.3.1. Medications
14.3.1.1. Anti-anxiety medications
14.3.1.2. Antipsychotic drugs
14.3.1.3. Antidepressants
14.3.1.4. Sleeping pills
14.3.1.5. Mood Stabilizer
14.3.2. Psychotherapy
14.3.2.1. Interpersonal and Social Rhythm Therapy (IPSRT)
14.3.2.2. Cognitive Behavioral Therapy (CBT)
14.3.2.3. Psychoeducation
14.3.2.4. Family-focused therapy
14.3.3. Electroconvulsive therapy (ECT)
14.3.4. Transcranial Magnetic Stimulation (TMS)
14.3.5. Others
14.4. Asia
Pacific Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Age Group
14.4.1. Children and Adolescents
14.4.2. Adults
14.4.3. Geriatric
14.5. Asia
Pacific Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
14.5.1. Hospitals and Clinics
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.5.4. Therapy Centers
14.6. Asia
Pacific Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
14.6.1.1.1. Bipolar I Disorder
14.6.1.1.2. Bipolar II Disorder
14.6.1.1.3. Cyclothymic Disorder
14.6.1.1.4. Rapid cycling bipolar
14.6.1.1.5. Bipolar with mixed features
14.6.1.1.6. Bipolar with seasonal pattern
14.6.1.1.7. Unspecified bipolar
14.6.1.2. China Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
14.6.1.2.1. Medications
14.6.1.2.1.1. Anti-anxiety
medications
14.6.1.2.1.2. Antipsychotic
drugs
14.6.1.2.1.3. Antidepressants
14.6.1.2.1.4. Sleeping
pills
14.6.1.2.1.5. Mood
Stabilizer
14.6.1.2.2. Psychotherapy
14.6.1.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.1.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.1.2.2.3. Psychoeducation
14.6.1.2.2.4. Family-focused
therapy
14.6.1.2.3. Electroconvulsive therapy (ECT)
14.6.1.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.1.2.5. Others
14.6.1.3. China Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
14.6.1.3.1. Children and Adolescents
14.6.1.3.2. Adults
14.6.1.3.3. Geriatric
14.6.1.4. China Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Retail Pharmacies
14.6.1.4.3. Online Pharmacies
14.6.1.4.4. Therapy Centers
14.6.2. Japan
14.6.2.1. Japan Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
14.6.2.1.1. Bipolar I Disorder
14.6.2.1.2. Bipolar II Disorder
14.6.2.1.3. Cyclothymic Disorder
14.6.2.1.4. Rapid cycling bipolar
14.6.2.1.5. Bipolar with mixed features
14.6.2.1.6. Bipolar with seasonal pattern
14.6.2.1.7. Unspecified bipolar
14.6.2.2. Japan Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
14.6.2.2.1. Medications
14.6.2.2.1.1. Anti-anxiety
medications
14.6.2.2.1.2. Antipsychotic
drugs
14.6.2.2.1.3. Antidepressants
14.6.2.2.1.4. Sleeping
pills
14.6.2.2.1.5. Mood
Stabilizer
14.6.2.2.2. Psychotherapy
14.6.2.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.2.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.2.2.2.3. Psychoeducation
14.6.2.2.2.4. Family-focused
therapy
14.6.2.2.3. Electroconvulsive therapy (ECT)
14.6.2.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.2.2.5. Others
14.6.2.3. Japan Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
14.6.2.3.1. Children and Adolescents
14.6.2.3.2. Adults
14.6.2.3.3. Geriatric
14.6.2.4. Japan Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Retail Pharmacies
14.6.2.4.3. Online Pharmacies
14.6.2.4.4. Therapy Centers
14.6.3. India
14.6.3.1. India Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
14.6.3.1.1. Bipolar I Disorder
14.6.3.1.2. Bipolar II Disorder
14.6.3.1.3. Cyclothymic Disorder
14.6.3.1.4. Rapid cycling bipolar
14.6.3.1.5. Bipolar with mixed features
14.6.3.1.6. Bipolar with seasonal pattern
14.6.3.1.7. Unspecified bipolar
14.6.3.2. India Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
14.6.3.2.1. Medications
14.6.3.2.1.1. Anti-anxiety
medications
14.6.3.2.1.2. Antipsychotic
drugs
14.6.3.2.1.3. Antidepressants
14.6.3.2.1.4. Sleeping
pills
14.6.3.2.1.5. Mood
Stabilizer
14.6.3.2.2. Psychotherapy
14.6.3.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.3.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.3.2.2.3. Psychoeducation
14.6.3.2.2.4. Family-focused
therapy
14.6.3.2.3. Electroconvulsive therapy (ECT)
14.6.3.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.3.2.5. Others
14.6.3.3. India Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
14.6.3.3.1. Children and Adolescents
14.6.3.3.2. Adults
14.6.3.3.3. Geriatric
14.6.3.4. India Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Retail Pharmacies
14.6.3.4.3. Online Pharmacies
14.6.3.4.4. Therapy Centers
14.6.4. New Zealand
14.6.4.1. New Zealand Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
14.6.4.1.1. Bipolar I Disorder
14.6.4.1.2. Bipolar II Disorder
14.6.4.1.3. Cyclothymic Disorder
14.6.4.1.4. Rapid cycling bipolar
14.6.4.1.5. Bipolar with mixed features
14.6.4.1.6. Bipolar with seasonal pattern
14.6.4.1.7. Unspecified bipolar
14.6.4.2. New Zealand Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
14.6.4.2.1. Medications
14.6.4.2.1.1. Anti-anxiety
medications
14.6.4.2.1.2. Antipsychotic
drugs
14.6.4.2.1.3. Antidepressants
14.6.4.2.1.4. Sleeping
pills
14.6.4.2.1.5. Mood
Stabilizer
14.6.4.2.2. Psychotherapy
14.6.4.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.4.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.4.2.2.3. Psychoeducation
14.6.4.2.2.4. Family-focused
therapy
14.6.4.2.3. Electroconvulsive therapy (ECT)
14.6.4.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.4.2.5. Others
14.6.4.3. New Zealand Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.6.4.3.1. Children and Adolescents
14.6.4.3.2. Adults
14.6.4.3.3. Geriatric
14.6.4.4. New Zealand Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Retail Pharmacies
14.6.4.4.3. Online Pharmacies
14.6.4.4.4. Therapy Centers
14.6.5. Australia
14.6.5.1. Australia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
14.6.5.1.1. Bipolar I Disorder
14.6.5.1.2. Bipolar II Disorder
14.6.5.1.3. Cyclothymic Disorder
14.6.5.1.4. Rapid cycling bipolar
14.6.5.1.5. Bipolar with mixed features
14.6.5.1.6. Bipolar with seasonal pattern
14.6.5.1.7. Unspecified bipolar
14.6.5.2. Australia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.6.5.2.1. Medications
14.6.5.2.1.1. Anti-anxiety
medications
14.6.5.2.1.2. Antipsychotic
drugs
14.6.5.2.1.3. Antidepressants
14.6.5.2.1.4. Sleeping
pills
14.6.5.2.1.5. Mood
Stabilizer
14.6.5.2.2. Psychotherapy
14.6.5.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.5.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.5.2.2.3. Psychoeducation
14.6.5.2.2.4. Family-focused
therapy
14.6.5.2.3. Electroconvulsive therapy (ECT)
14.6.5.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.5.2.5. Others
14.6.5.3. Australia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.6.5.3.1. Children and Adolescents
14.6.5.3.2. Adults
14.6.5.3.3. Geriatric
14.6.5.4. Australia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Retail Pharmacies
14.6.5.4.3. Online Pharmacies
14.6.5.4.4. Therapy Centers
14.6.6. South Korea
14.6.6.1. South Korea Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
14.6.6.1.1. Bipolar I Disorder
14.6.6.1.2. Bipolar II Disorder
14.6.6.1.3. Cyclothymic Disorder
14.6.6.1.4. Rapid cycling bipolar
14.6.6.1.5. Bipolar with mixed features
14.6.6.1.6. Bipolar with seasonal pattern
14.6.6.1.7. Unspecified bipolar
14.6.6.2. South Korea Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.6.6.2.1. Medications
14.6.6.2.1.1. Anti-anxiety
medications
14.6.6.2.1.2. Antipsychotic
drugs
14.6.6.2.1.3. Antidepressants
14.6.6.2.1.4. Sleeping
pills
14.6.6.2.1.5. Mood
Stabilizer
14.6.6.2.2. Psychotherapy
14.6.6.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.6.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.6.2.2.3. Psychoeducation
14.6.6.2.2.4. Family-focused
therapy
14.6.6.2.3. Electroconvulsive therapy (ECT)
14.6.6.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.6.2.5. Others
14.6.6.3. South Korea Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.6.6.3.1. Children and Adolescents
14.6.6.3.2. Adults
14.6.6.3.3. Geriatric
14.6.6.4. South Korea Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Retail Pharmacies
14.6.6.4.3. Online Pharmacies
14.6.6.4.4. Therapy Centers
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
14.6.7.1.1. Bipolar I Disorder
14.6.7.1.2. Bipolar II Disorder
14.6.7.1.3. Cyclothymic Disorder
14.6.7.1.4. Rapid cycling bipolar
14.6.7.1.5. Bipolar with mixed features
14.6.7.1.6. Bipolar with seasonal pattern
14.6.7.1.7. Unspecified bipolar
14.6.7.2. Southeast Asia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
14.6.7.2.1. Medications
14.6.7.2.1.1. Anti-anxiety
medications
14.6.7.2.1.2. Antipsychotic
drugs
14.6.7.2.1.3. Antidepressants
14.6.7.2.1.4. Sleeping
pills
14.6.7.2.1.5. Mood
Stabilizer
14.6.7.2.2. Psychotherapy
14.6.7.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.7.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.7.2.2.3. Psychoeducation
14.6.7.2.2.4. Family-focused
therapy
14.6.7.2.3. Electroconvulsive therapy (ECT)
14.6.7.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.7.2.5. Others
14.6.7.3. Southeast Asia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.6.7.3.1. Children and Adolescents
14.6.7.3.2. Adults
14.6.7.3.3. Geriatric
14.6.7.4. Southeast Asia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Retail Pharmacies
14.6.7.4.3. Online Pharmacies
14.6.7.4.4. Therapy Centers
14.6.7.5. Southeast Asia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Type of Bipolar Disorder
14.6.8.1.1. Bipolar I Disorder
14.6.8.1.2. Bipolar II Disorder
14.6.8.1.3. Cyclothymic Disorder
14.6.8.1.4. Rapid cycling bipolar
14.6.8.1.5. Bipolar with mixed features
14.6.8.1.6. Bipolar with seasonal pattern
14.6.8.1.7. Unspecified bipolar
14.6.8.2. Rest of Asia Pacific Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Treatment Type
14.6.8.2.1. Medications
14.6.8.2.1.1. Anti-anxiety
medications
14.6.8.2.1.2. Antipsychotic
drugs
14.6.8.2.1.3. Antidepressants
14.6.8.2.1.4. Sleeping
pills
14.6.8.2.1.5. Mood
Stabilizer
14.6.8.2.2. Psychotherapy
14.6.8.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
14.6.8.2.2.2. Cognitive
Behavioral Therapy (CBT)
14.6.8.2.2.3. Psychoeducation
14.6.8.2.2.4. Family-focused
therapy
14.6.8.2.3. Electroconvulsive therapy (ECT)
14.6.8.2.4. Transcranial Magnetic Stimulation (TMS)
14.6.8.2.5. Others
14.6.8.3. Rest of Asia Pacific Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Age Group
14.6.8.3.1. Children and Adolescents
14.6.8.3.2. Adults
14.6.8.3.3. Geriatric
14.6.8.4. Rest of Asia Pacific Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Retail Pharmacies
14.6.8.4.3. Online Pharmacies
14.6.8.4.4. Therapy Centers
14.7. Key
Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Type of Bipolar Disorder
14.7.3. By Treatment Type
14.7.4. By Age Group
14.7.5. By Sales Channel
15. Middle East and Africa Bipolar Disorder Market Analysis and
Forecasts, 2023 – 2031
15.1. Overview
15.1.1. Middle East and Africa Bipolar Disorder Market Revenue (US$
Mn)
15.2. Middle
East and Africa Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Type
of Bipolar Disorder
15.2.1. Bipolar I Disorder
15.2.2. Bipolar II Disorder
15.2.3. Cyclothymic Disorder
15.2.4. Rapid cycling bipolar
15.2.5. Bipolar with mixed features
15.2.6. Bipolar with seasonal pattern
15.2.7. Unspecified bipolar
15.3. Middle
East and Africa Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.3.1. Medications
15.3.1.1. Anti-anxiety medications
15.3.1.2. Antipsychotic drugs
15.3.1.3. Antidepressants
15.3.1.4. Sleeping pills
15.3.1.5. Mood Stabilizer
15.3.2. Psychotherapy
15.3.2.1. Interpersonal and Social Rhythm Therapy (IPSRT)
15.3.2.2. Cognitive Behavioral Therapy (CBT)
15.3.2.3. Psychoeducation
15.3.2.4. Family-focused therapy
15.3.3. Electroconvulsive therapy (ECT)
15.3.4. Transcranial Magnetic Stimulation (TMS)
15.3.5. Others
15.4. Middle
East and Africa Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Age
Group
15.4.1. Children and Adolescents
15.4.2. Adults
15.4.3. Geriatric
15.5. Middle
East and Africa Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Sales Channel
15.5.1. Hospitals and Clinics
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.5.4. Therapy Centers
15.6. Middle
East and Africa Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
15.6.1.1.1. Bipolar I Disorder
15.6.1.1.2. Bipolar II Disorder
15.6.1.1.3. Cyclothymic Disorder
15.6.1.1.4. Rapid cycling bipolar
15.6.1.1.5. Bipolar with mixed features
15.6.1.1.6. Bipolar with seasonal pattern
15.6.1.1.7. Unspecified bipolar
15.6.1.2. Saudi Arabia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
15.6.1.2.1. Medications
15.6.1.2.1.1. Anti-anxiety
medications
15.6.1.2.1.2. Antipsychotic
drugs
15.6.1.2.1.3. Antidepressants
15.6.1.2.1.4. Sleeping
pills
15.6.1.2.1.5. Mood
Stabilizer
15.6.1.2.2. Psychotherapy
15.6.1.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
15.6.1.2.2.2. Cognitive
Behavioral Therapy (CBT)
15.6.1.2.2.3. Psychoeducation
15.6.1.2.2.4. Family-focused
therapy
15.6.1.2.3. Electroconvulsive therapy (ECT)
15.6.1.2.4. Transcranial Magnetic Stimulation (TMS)
15.6.1.2.5. Others
15.6.1.3. Saudi Arabia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.6.1.3.1. Children and Adolescents
15.6.1.3.2. Adults
15.6.1.3.3. Geriatric
15.6.1.4. Saudi Arabia Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Retail Pharmacies
15.6.1.4.3. Online Pharmacies
15.6.1.4.4. Therapy Centers
15.6.2. UAE
15.6.2.1. UAE Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Type of Bipolar Disorder
15.6.2.1.1. Bipolar I Disorder
15.6.2.1.2. Bipolar II Disorder
15.6.2.1.3. Cyclothymic Disorder
15.6.2.1.4. Rapid cycling bipolar
15.6.2.1.5. Bipolar with mixed features
15.6.2.1.6. Bipolar with seasonal pattern
15.6.2.1.7. Unspecified bipolar
15.6.2.2. UAE Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Treatment Type
15.6.2.2.1. Medications
15.6.2.2.1.1. Anti-anxiety
medications
15.6.2.2.1.2. Antipsychotic
drugs
15.6.2.2.1.3. Antidepressants
15.6.2.2.1.4. Sleeping
pills
15.6.2.2.1.5. Mood
Stabilizer
15.6.2.2.2. Psychotherapy
15.6.2.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
15.6.2.2.2.2. Cognitive
Behavioral Therapy (CBT)
15.6.2.2.2.3. Psychoeducation
15.6.2.2.2.4. Family-focused
therapy
15.6.2.2.3. Electroconvulsive therapy (ECT)
15.6.2.2.4. Transcranial Magnetic Stimulation (TMS)
15.6.2.2.5. Others
15.6.2.3. UAE Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Age Group
15.6.2.3.1. Children and Adolescents
15.6.2.3.2. Adults
15.6.2.3.3. Geriatric
15.6.2.4. UAE Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By
Sales Channel
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Retail Pharmacies
15.6.2.4.3. Online Pharmacies
15.6.2.4.4. Therapy Centers
15.6.3. Egypt
15.6.3.1. Egypt Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
15.6.3.1.1. Bipolar I Disorder
15.6.3.1.2. Bipolar II Disorder
15.6.3.1.3. Cyclothymic Disorder
15.6.3.1.4. Rapid cycling bipolar
15.6.3.1.5. Bipolar with mixed features
15.6.3.1.6. Bipolar with seasonal pattern
15.6.3.1.7. Unspecified bipolar
15.6.3.2. Egypt Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
15.6.3.2.1. Medications
15.6.3.2.1.1. Anti-anxiety
medications
15.6.3.2.1.2. Antipsychotic
drugs
15.6.3.2.1.3. Antidepressants
15.6.3.2.1.4. Sleeping
pills
15.6.3.2.1.5. Mood
Stabilizer
15.6.3.2.2. Psychotherapy
15.6.3.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
15.6.3.2.2.2. Cognitive
Behavioral Therapy (CBT)
15.6.3.2.2.3. Psychoeducation
15.6.3.2.2.4. Family-focused
therapy
15.6.3.2.3. Electroconvulsive therapy (ECT)
15.6.3.2.4. Transcranial Magnetic Stimulation (TMS)
15.6.3.2.5. Others
15.6.3.3. Egypt Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.6.3.3.1. Children and Adolescents
15.6.3.3.2. Adults
15.6.3.3.3. Geriatric
15.6.3.4. Egypt Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Retail Pharmacies
15.6.3.4.3. Online Pharmacies
15.6.3.4.4. Therapy Centers
15.6.4. Kuwait
15.6.4.1. Kuwait Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
15.6.4.1.1. Bipolar I Disorder
15.6.4.1.2. Bipolar II Disorder
15.6.4.1.3. Cyclothymic Disorder
15.6.4.1.4. Rapid cycling bipolar
15.6.4.1.5. Bipolar with mixed features
15.6.4.1.6. Bipolar with seasonal pattern
15.6.4.1.7. Unspecified bipolar
15.6.4.2. Kuwait Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
15.6.4.2.1. Medications
15.6.4.2.1.1. Anti-anxiety
medications
15.6.4.2.1.2. Antipsychotic
drugs
15.6.4.2.1.3. Antidepressants
15.6.4.2.1.4. Sleeping
pills
15.6.4.2.1.5. Mood
Stabilizer
15.6.4.2.2. Psychotherapy
15.6.4.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
15.6.4.2.2.2. Cognitive
Behavioral Therapy (CBT)
15.6.4.2.2.3. Psychoeducation
15.6.4.2.2.4. Family-focused
therapy
15.6.4.2.3. Electroconvulsive therapy (ECT)
15.6.4.2.4. Transcranial Magnetic Stimulation (TMS)
15.6.4.2.5. Others
15.6.4.3. Kuwait Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.6.4.3.1. Children and Adolescents
15.6.4.3.2. Adults
15.6.4.3.3. Geriatric
15.6.4.4. Kuwait Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Retail Pharmacies
15.6.4.4.3. Online Pharmacies
15.6.4.4.4. Therapy Centers
15.6.5. South Africa
15.6.5.1. South Africa Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
15.6.5.1.1. Bipolar I Disorder
15.6.5.1.2. Bipolar II Disorder
15.6.5.1.3. Cyclothymic Disorder
15.6.5.1.4. Rapid cycling bipolar
15.6.5.1.5. Bipolar with mixed features
15.6.5.1.6. Bipolar with seasonal pattern
15.6.5.1.7. Unspecified bipolar
15.6.5.2. South Africa Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
15.6.5.2.1. Medications
15.6.5.2.1.1. Anti-anxiety
medications
15.6.5.2.1.2. Antipsychotic
drugs
15.6.5.2.1.3. Antidepressants
15.6.5.2.1.4. Sleeping
pills
15.6.5.2.1.5. Mood
Stabilizer
15.6.5.2.2. Psychotherapy
15.6.5.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
15.6.5.2.2.2. Cognitive
Behavioral Therapy (CBT)
15.6.5.2.2.3. Psychoeducation
15.6.5.2.2.4. Family-focused
therapy
15.6.5.2.3. Electroconvulsive therapy (ECT)
15.6.5.2.4. Transcranial Magnetic Stimulation (TMS)
15.6.5.2.5. Others
15.6.5.3. South Africa Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.6.5.3.1. Children and Adolescents
15.6.5.3.2. Adults
15.6.5.3.3. Geriatric
15.6.5.4. South Africa Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Retail Pharmacies
15.6.5.4.3. Online Pharmacies
15.6.5.4.4. Therapy Centers
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Bipolar Disorder Market
Revenue (US$ Mn) and Forecasts, By Type of Bipolar Disorder
15.6.6.1.1. Bipolar I Disorder
15.6.6.1.2. Bipolar II Disorder
15.6.6.1.3. Cyclothymic Disorder
15.6.6.1.4. Rapid cycling bipolar
15.6.6.1.5. Bipolar with mixed features
15.6.6.1.6. Bipolar with seasonal pattern
15.6.6.1.7. Unspecified bipolar
15.6.6.2. Rest of Middle East & Africa Bipolar Disorder Market
Revenue (US$ Mn) and Forecasts, By Treatment Type
15.6.6.2.1. Medications
15.6.6.2.1.1. Anti-anxiety
medications
15.6.6.2.1.2. Antipsychotic
drugs
15.6.6.2.1.3. Antidepressants
15.6.6.2.1.4. Sleeping
pills
15.6.6.2.1.5. Mood
Stabilizer
15.6.6.2.2. Psychotherapy
15.6.6.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
15.6.6.2.2.2. Cognitive
Behavioral Therapy (CBT)
15.6.6.2.2.3. Psychoeducation
15.6.6.2.2.4. Family-focused
therapy
15.6.6.2.3. Electroconvulsive therapy (ECT)
15.6.6.2.4. Transcranial Magnetic Stimulation (TMS)
15.6.6.2.5. Others
15.6.6.3. Rest of Middle East & Africa Bipolar Disorder Market
Revenue (US$ Mn) and Forecasts, By Age Group
15.6.6.3.1. Children and Adolescents
15.6.6.3.2. Adults
15.6.6.3.3. Geriatric
15.6.6.4. Rest of Middle East & Africa Bipolar Disorder Market
Revenue (US$ Mn) and Forecasts, By Sales Channel
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Retail Pharmacies
15.6.6.4.3. Online Pharmacies
15.6.6.4.4. Therapy Centers
15.7. Key
Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Type of Bipolar Disorder
15.7.3. By Treatment Type
15.7.4. By Age Group
15.7.5. By Sales Channel
16. Latin America Bipolar Disorder Market Analysis and Forecasts,
2023 – 2031
16.1. Overview
16.1.1. Latin America Bipolar Disorder Market Revenue (US$ Mn)
16.2. Latin
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Type of
Bipolar Disorder
16.2.1. Bipolar I Disorder
16.2.2. Bipolar II Disorder
16.2.3. Cyclothymic Disorder
16.2.4. Rapid cycling bipolar
16.2.5. Bipolar with mixed features
16.2.6. Bipolar with seasonal pattern
16.2.7. Unspecified bipolar
16.3. Latin
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Treatment
Type
16.3.1. Medications
16.3.1.1. Anti-anxiety medications
16.3.1.2. Antipsychotic drugs
16.3.1.3. Antidepressants
16.3.1.4. Sleeping pills
16.3.1.5. Mood Stabilizer
16.3.2. Psychotherapy
16.3.2.1. Interpersonal and Social Rhythm Therapy (IPSRT)
16.3.2.2. Cognitive Behavioral Therapy (CBT)
16.3.2.3. Psychoeducation
16.3.2.4. Family-focused therapy
16.3.3. Electroconvulsive therapy (ECT)
16.3.4. Transcranial Magnetic Stimulation (TMS)
16.3.5. Others
16.4. Latin
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Age Group
16.4.1. Children and Adolescents
16.4.2. Adults
16.4.3. Geriatric
16.5. Latin America
Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.5.1. Hospitals and Clinics
16.5.2. Retail Pharmacies
16.5.3. Online Pharmacies
16.5.4. Therapy Centers
16.6. Latin
America Bipolar Disorder Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Type of Bipolar Disorder
16.6.1.1.1. Bipolar I Disorder
16.6.1.1.2. Bipolar II Disorder
16.6.1.1.3. Cyclothymic Disorder
16.6.1.1.4. Rapid cycling bipolar
16.6.1.1.5. Bipolar with mixed features
16.6.1.1.6. Bipolar with seasonal pattern
16.6.1.1.7. Unspecified bipolar
16.6.1.2. Brazil Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Treatment Type
16.6.1.2.1. Medications
16.6.1.2.1.1. Anti-anxiety
medications
16.6.1.2.1.2. Antipsychotic
drugs
16.6.1.2.1.3. Antidepressants
16.6.1.2.1.4. Sleeping
pills
16.6.1.2.1.5. Mood
Stabilizer
16.6.1.2.2. Psychotherapy
16.6.1.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
16.6.1.2.2.2. Cognitive
Behavioral Therapy (CBT)
16.6.1.2.2.3. Psychoeducation
16.6.1.2.2.4. Family-focused
therapy
16.6.1.2.3. Electroconvulsive therapy (ECT)
16.6.1.2.4. Transcranial Magnetic Stimulation (TMS)
16.6.1.2.5. Others
16.6.1.3. Brazil Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.6.1.3.1. Children and Adolescents
16.6.1.3.2. Adults
16.6.1.3.3. Geriatric
16.6.1.4. Brazil Bipolar Disorder Market Revenue (US$ Mn) and Forecasts,
By Sales Channel
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Retail Pharmacies
16.6.1.4.3. Online Pharmacies
16.6.1.4.4. Therapy Centers
16.6.2. Argentina
16.6.2.1. Argentina Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Type of Bipolar Disorder
16.6.2.1.1. Bipolar I Disorder
16.6.2.1.2. Bipolar II Disorder
16.6.2.1.3. Cyclothymic Disorder
16.6.2.1.4. Rapid cycling bipolar
16.6.2.1.5. Bipolar with mixed features
16.6.2.1.6. Bipolar with seasonal pattern
16.6.2.1.7. Unspecified bipolar
16.6.2.2. Argentina Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Treatment Type
16.6.2.2.1. Medications
16.6.2.2.1.1. Anti-anxiety
medications
16.6.2.2.1.2. Antipsychotic
drugs
16.6.2.2.1.3. Antidepressants
16.6.2.2.1.4. Sleeping
pills
16.6.2.2.1.5. Mood
Stabilizer
16.6.2.2.2. Psychotherapy
16.6.2.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
16.6.2.2.2.2. Cognitive
Behavioral Therapy (CBT)
16.6.2.2.2.3. Psychoeducation
16.6.2.2.2.4. Family-focused
therapy
16.6.2.2.3. Electroconvulsive therapy (ECT)
16.6.2.2.4. Transcranial Magnetic Stimulation (TMS)
16.6.2.2.5. Others
16.6.2.3. Argentina Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.6.2.3.1. Children and Adolescents
16.6.2.3.2. Adults
16.6.2.3.3. Geriatric
16.6.2.4. Argentina Bipolar Disorder Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Retail Pharmacies
16.6.2.4.3. Online Pharmacies
16.6.2.4.4. Therapy Centers
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Type of Bipolar Disorder
16.6.3.1.1. Bipolar I Disorder
16.6.3.1.2. Bipolar II Disorder
16.6.3.1.3. Cyclothymic Disorder
16.6.3.1.4. Rapid cycling bipolar
16.6.3.1.5. Bipolar with mixed features
16.6.3.1.6. Bipolar with seasonal pattern
16.6.3.1.7. Unspecified bipolar
16.6.3.2. Rest of Latin America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Treatment Type
16.6.3.2.1. Medications
16.6.3.2.1.1. Anti-anxiety
medications
16.6.3.2.1.2. Antipsychotic
drugs
16.6.3.2.1.3. Antidepressants
16.6.3.2.1.4. Sleeping
pills
16.6.3.2.1.5. Mood
Stabilizer
16.6.3.2.2. Psychotherapy
16.6.3.2.2.1. Interpersonal
and Social Rhythm Therapy (IPSRT)
16.6.3.2.2.2. Cognitive
Behavioral Therapy (CBT)
16.6.3.2.2.3. Psychoeducation
16.6.3.2.2.4. Family-focused
therapy
16.6.3.2.3. Electroconvulsive therapy (ECT)
16.6.3.2.4. Transcranial Magnetic Stimulation (TMS)
16.6.3.2.5. Others
16.6.3.3. Rest of Latin America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Age Group
16.6.3.3.1. Children and Adolescents
16.6.3.3.2. Adults
16.6.3.3.3. Geriatric
16.6.3.4. Rest of Latin America Bipolar Disorder Market Revenue (US$ Mn)
and Forecasts, By Sales Channel
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Retail Pharmacies
16.6.3.4.3. Online Pharmacies
16.6.3.4.4. Therapy Centers
16.7. Key
Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Type of Bipolar Disorder
16.7.3. By Treatment Type
16.7.4. By Age Group
16.7.5. By Sales Channel
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2022
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. Alembic
Pharmaceuticals
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. AbbVie
Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Astellas
Pharma Inc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. AstraZeneca
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Eli Lilly
and Company
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. GSK plc.
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Otsuka
Pharmaceutical Co., Ltd.
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Pfizer
Inc
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Validus
Pharmaceuticals, Inc.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Other
market participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.